At ISS we know the importance of understanding your audience at an FDA AdComm – what are their backgrounds, are they motivated by a particular cause or issue? Based on our knowledge we are happy to kick-off the ISS roll call blog – a designated reporter of the changes to the FDA Drug AdComm members.
This month we saw a change in a well-known committee – 4 members of the Drug Safety and Risk Management Advisory Committee (DSaRM) have the left the committee. Drs. William Cooper, Peter Kaboli, Elaine Morrato and T. Mark Woods have all reach the end of the terms this past month. DSaRM now has four vacancies to fill and we wait anxiously to see who fills those spots.
The Anesthetic and Analgesic Drugs Advisory Committee has also seen some departures this month. It was the end of term for Drs. Edward Covington, John Markman and Mr. Knox Todd. Consumer representative Penny Cowan has also reached the end of her term. The departure of these members leaves a total of 6 vacancies on this committee.
Heading into the summer we will be regularly scanning the committees to report on new additions to these and all other FDA Drug AdComms. Click here for the current remaining DSaRM committee and here for the remaining Anesthetic and Analgesics Drugs committee.
Stay tuned for our next blog post where we will put the spotlight on one of the hottest AdComms – the Oncologic Drug Advisory Committee.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact email@example.com.